The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management
| ambulatory_alcohol_withdrawal_management_asam_2020_cpg.pdf |
Applying the ASAM NPG: Ambulatory Withdrawal Management for People Experiencing Homelessness During COVID-19 - Brian Hurley, MD
| ambulatory_alcohol_withdrawal_management_asam_cpg_application_to_homeless_presentation_by_hurley_4-2021.pdf |
Ambulatory Alcohol Withdrawal Management - Anika A. H. Alvanzo, MD
| ambulatory_alcohol_withdrawal_management_avanzo_presentation_4-2021.pdf |
Principles of Addiction Medicine: High Impact Research from 2020 (& early 2021) - Sarah E. Wakeman MD Joshua D Lee MD MSc
| annual_journal_review_of_pain___addiction_medicine_part_one_-_key_publications_from_2020-2021.pdf |
Annual Review of Pain & Addiction Medicine: Key Publications from 2020-2021 William S. Jacobs MD, Launette M. Rieb, MD, Gregory Rudolf, MD
| annual_journal_review_of_addiction_medicine_part_two_-_highest_impact_publications_2020-2021.pdf |
ATLAS™ Quality Measures Overview. ATLAS is the first of its kind quality measurement system for addiction treatment facilities.
| atlas__quality_measures_overview.pdf |
ATLAS®: Using Data to Measure and Improve Addiction Treatment Quality Shannon Biello, MPH; Channah VanRegenmorter, MSSW, PMP; & Julie Seibert, PhD, MPH
| atlas_-_using_data_to_measure_and_improve_addiction_treatment.pdf |
Behavioral Health: Techniques, Referrals, & Talking to Your Patients About Counseling Sharon Hsu, Ph.D.
| behavioral_health_counseling.pdf |
Buprenorphine—Taper or Continue for Life? James Berry, MD
| buprenorphine_-_taper_or_continue_for_life.pdf |
Bupropion and Naltrexone in Methamphetamine Use Disorder Madhukar H. Trivedi, M.D
| bupropion_and_naltrexone_in_tx_methamphetamine_use_disorder.pdf |
Cannabinoidiol and Covid - Gregory Bunt, M.D.
| cannabinoids_and_covid-19.pdf |
Cannabis / Cannabinoids as Medicine: Are we there? - Gregory Bunt, M.D.
| cannabis_cannabinoids_as_medicine_-_there_yet.pdf |
CARING FOR YOURSELF IN THE FACE OF DIFFICULT WORK
Our work can be overwhelming. Our challenge is to maintain our resilience so that we can keep doing the work with care, energy, and compassion.
Our work can be overwhelming. Our challenge is to maintain our resilience so that we can keep doing the work with care, energy, and compassion.
| caring_for_yourself_in_the_face_of_difficult_work.pdf |
Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention - Journal of Substance Abuse Treatment 2021
| choice_of_extended_release_medication_for_oud_in_young_adults_-_buprenorphine_or_naltrexone.pdf |
Which of the five sexuality circles feels most familiar? (and have impact on Recovery)
| circles_of_sexuality.pdf |
Clinical Considerations for Sexuality Issues in Substance Abuse Recovery - Jenn DiBartolomeo, M.A. (she/her)
| clinical_considerations_for_sexuality_in_sud_recovery.pdf |
Contingency Management Implementation: Strengthening MAT in Primary Care Angela Colistra, PhD, LPC, CAADC, CCS, Sophia Harbove, MS, CTP Yamelisa J. Taveras, MA, CAADC, CCS, Abby Letcher, MD, FASAM, Acknowledgement: Nyann Biery, MS
| contingency_management_implementation_in_primary_care_for_mat.pdf |
Critical Conversations: Discussing Fertility Plans with Women with Substance Use Disorders - Sara Spinella, MD Diana Samberg, MD, MS
| discussing_fertility_plans_with_women_with_sud_spinella.pdf |
No Harm: Racial bias, Medicine, Addiction, and the drug war - Kassandra Frederique Drug Policy Alliance
| do_no_harm_-_racial_bias_in_addiction.pdf |
ED-Initiated Buprenorphine for Opioid Use Disorder - Gail D’Onofrio MD
| ed-initiated_buprenorphine_for_oud.pdf |
Education, the Best Analgesic: New Concepts in Opioid Sparing Options for Pain - Alexis M. LaPietra, DO
| education_the_best_analgesic_-_new_concepts_in_opioid_sparing_for_pain_management.pdf |
Evaluation and Treatment of Opioid Use Disorders in Remote Areas with Telemedicine Anthony Dekker DO and Patricia Anne Roe PsyD PMHNP-BC
| evaluation_and_treatment_of_opioid_use_disorder_in_remote_areas_with_telemedicine.pdf |
Hyperalgesia and Hyperkatifeia - George F. Koob, Ph.D. - (Mortality, Drugs, and Deaths of Despair in the United States)
| hyperalgesia___hyperkatifeia_by_koop.pdf |
Implementing outpatient alcohol withdrawal management into primary care - Joshua Blum MD, Matthew Hoag LPC, J Cram LAC, Jess Bull MD
| implementing_outpatient_alcohol_withdrawal_management.pdf |
Improving the Treatment of Pain and Addiction for Your Patients of Color - Johnathan Goree, MD
| improving_the_treatment_of_pain_-_addiction_for_your_patients_of_color.pdf |
Improving Treatment of OUD in Youth: The Youth Opioid Recovery Support (YORS) Intervention - Marc Fishman, MD
| improving_treatment_of_oud_in_youth.pdf |
Induction Without Withdrawal: Buprenorphine/Naloxone Micro-Dosing - Pouya Azar, MD, Nickie Mathew, MD, James Wong, BS
| induction_without_withdrawal_-_buprenorphine_microdosing.pdf |
Integrating Hepatitis C Treatment Into Routine Treatment of Substance Use Disorders Deanna Wilson MD, Divya Venkat, MD, Hannah Cawoski, PharmD, Stephanie Klipp, RN
| integrating_hepatitis_c_treatment_into_routine_tx_of_sud.pdf |
Interdisciplinary Approaches to Outpatient Addiction Treatment for Vulnerable Youth - Paula Goldman, MD, Alicia Boykin, MD, Megana Dwarakanath, MD , Kathryn Rehberg, MSW – Social Worker, Kaila Venezia, BSW , Deanna Wilson, MD
| interdisciplinary_approaches_to_outpt_addiction_tx_for_vulnerable_youth.pdf |
Lessons Learned From Buprenorphine Telehealth During COVID-19: A Guide For Providers
| lessons_-_telehealth_oud_tx_during_covid-19_pandemic.pdf |
|
Managing Acute and Chronic Pain in Patients with Opioid Use Disorder - Amy J. Kennedy, MD, Brian Hurley, MD, Stephanie Klipp, RN, J. Deanna Wilson, MD
|
| ||
|
The Neurobiology of Trauma: including Historic and Intergenerational Trauma
on the Development of Addictions and Eating Disorders - Carolyn Coker Ross, MD |
| ||
Parallel Pharmaceutical & Alternative Opioid Agonist Therapies to Treat Opioid Use Disorder - Stephanie T. Weiss, MD, Lewis S. Nelson, MD
| parallel_pharmaceutical___alternative_opioid_agonist_tx_to_tx_oud.pdf |
Precipitated Opioid Withdrawal: When, Where, And What To Do Next - Rachel S. Wightman, MD JoAn Laes, MD Rachel Haroz, MD Lewis Nelson, MD
| precipitated_opioid_withdrawal_-_when_where_what_to_do_next.pdf |
Reaching our Most Vulnerable Patients with MAT through Long Acting Injectables - Arianna Campbell, PA-C Andrew Herring, MD Loni Jay, MD Aimee Moulin, MD Hannah Snyder, MD Monish Ullal, MD
| reaching_our_most_vulnerable_patients_with_mat_through_long_acting.pdf |
Recovery Capital Checklist - From Zweben JE, Sorensen JL, Shingle M, Blazes CK. Discontinuing methadone and buprenorphine: a review and clinical challenges. J addict med. 2020 Dec 15
| recovery_capital_checklist.pdf |
Rethinking Opioids for Pain: Current Research and Consideration - Daniel P. Alford, MD
| rethinking_opioids_for_pain_-_current_research___considerations.pdf |
Case report: Successful induction of buprenorphine/naloxone using a microdosing schedule and assertive outreach - Jennifer Rozylo , Keren Mitchell, Mohammadali Nikoo, S. Elise Durante, Skye P. Barbic, Daniel Lin, Steve Mathias, and Pouya Azar - Addict Sci Clin Pract (2020) 15:2
| successful_induction_with_buprenorphine_microdosing.pdf |
Telemedicine for opioid use disorder treatment in the age of Covid-19 - Lewei Lin MD, MS David Moore MD, PhD Larissa Mooney MD David Kan MD
| telemedicine_for_opioid_use_disorder_in_age_of_covid-19.pdf |
Using Mobile Services to Increase Access to Medications for Addiction Treatment - Carolina Close, MA; Donna B. Goldstrom, LPC, LAC; Tara Kerner, DO; Camara A. Wooten, BA
| using_mobile_services_to_increase_access_to_mat_for_oud.pdf |